Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

SML0326

Sigma-Aldrich

GTS-21

≥97% (HPLC)

Synonyme(s) :

3-(2,4-Dimethoxybenzylidene)-anabaseine dihydrochloride, DMBX-anabaseine, DMXB, DMXB-A, GTS21

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H20N2O2 · 2HCl
Numéro CAS:
156223-05-1
Poids moléculaire :
381.30
Numéro MDL:
MFCD00941364
Code UNSPSC :
12352200
ID de substance PubChem :
329825331
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥97% (HPLC)

Forme

powder

Couleur

faintly yellow to dark yellow

Solubilité

H2O: >5 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

Cl.Cl.COc1ccc(\C=C2/CCCN=C2c3cccnc3)c(OC)c1

InChI

1S/C19H20N2O2.2ClH/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16;;/h3,6-9,11-13H,4-5,10H2,1-2H3;2*1H/b15-11+;;

Clé InChI

BXKYFUGAAFLYJL-BXGYHSFXSA-N

Application

GTS-21 has been used:
  • as an α7 nicotinic acetylcholine receptors (nAChR) partial agonist to elucidate its anti-inflammatory effects in mouse macrophages
  • to test its protective effect on the renal injury induced by lipopolysaccharide (LPS)
  • to test its effect on microvascular inflammation in endotoxemia induced by LPS

Actions biochimiques/physiologiques

GTS-2, a derivative of anisine is an immunomodulatory drug. It is used for treating pancreatitis and septicemia. GTS-2 inhibits the pro-inflammatory cytokines especially the interleukin-6 (IL6) and tumor necrosis factor (TNF) in sepsis and endotoxemia.
GTS-21 is a selective agonist at α-7 nicotinic receptors with anti-inflammatory and cognition enhancing activities. GTS-21 has also been investigated for the treatment of schizophrenia.

Caractéristiques et avantages

This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Peng Sun et al.
Shock (Augusta, Ga.), 49(6), 698-703 (2017-08-12)
Studies have demonstrated that vagus nerve stimulation (VNS) reduces ischemia/reperfusion injury. In this study, we investigated the protective effects of VNS in a rat model of cardiopulmonary resuscitation (CPR). We further investigated whether the beneficial effects of VNS were dependent
Prodyot K Chatterjee et al.
PloS one, 7(5), e35361-e35361 (2012-05-16)
Sepsis is one of the leading causes of acute kidney injury (AKI). Septic patients who develop acute kidney injury (AKI) are at increased risk of death. To date there is no effective treatment for AKI or septic AKI. Based on
Jerry J Buccafusco et al.
Biochemical pharmacology, 78(7), 852-862 (2009-07-07)
In monkeys proficient in the performance of a computer-assisted delayed response task, administration of sub-sedative doses of ketamine significantly impaired task performance after the 2mg/kg dose, producing a decrease in accuracies across all four delay intervals. Ketamine elicited occasional and
Jason R Tregellas et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(4), 938-942 (2009-12-04)
3-(2,4-Dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at alpha7-nicotinic acetylcholine receptors and is now in early clinical development for treatment of deficits in neurocognition and sensory gating in schizophrenia. During its initial phase 2 test, functional magnetic resonance imaging (fMRI) studies
Christopher E Cannon et al.
Neuropharmacology, 64, 191-196 (2012-06-05)
The cognitive deficits associated with schizophrenia are recognized as a core component of the disorder, yet there remain no available therapeutics to treat these symptoms of the disease. As a result, there is a need for establishing predictive preclinical models
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique